This program uses very low, carefully dosed GLP-1 medication to support metabolic wellness over time without the appetite suppression or intensity associated with traditional GLP-1 weight loss protocols
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
2 People living with obesity face substantial bias and stigma, which contribute to poor health outcomes, including increased morbidity and mortality
(2023) Effects of onceweekly semaglutide on appetite, energy intake, control of eating, food preference, and body weight in subjects with obesity, Diabetes, Obesity, and Metabolism (2017) Insulin resistance/hyperinsulinemia: An important cardiovascular risk factor that has long been underestimated, Frontiers in Cardiovascular Medicine (2024) American Heart Association recommendations for physical activity in adults and kids, American Heart Association (2024) The role of the thyroid in polycystic ovary syndrome, Frontiers in Endocrinology (2023) When your weight gain is caused by medicine, University of Rochester Medical Center (2024) Stress, cortisol, and other appetite-related hormones: Prospective prediction of 6-month changes in food cravings and weight, Obesity (2017) Causal association between obesity and hypothyroidism: a two-sample bidirectional Mendelian randomization study, Frontiers in Endocrinology (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Feb 10, 2026 You have been on semaglutide for months
History of Thyroid Cancer or MEN 2: If you or a family member has had medullary thyroid carcinoma (a rare thyroid cancer) or multiple endocrine neoplasia syndrome type 2 (MEN 2), Ozempic is not recommended
